Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yamaguchi, T.
Right arrow Articles by Ogura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamaguchi, T.
Right arrow Articles by Ogura, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:53-58 (2000)
© 2000 Foundation for Promotion of Cancer Research

Effect of IL-6 Elevation in Malignant Pleural Effusion on Hyperfibrinogenemia in Lung Cancer Patients

Toshihiko Yamaguchi1, Hiromi Kimura1, Soichiro Yokota1, Yuko Yamamoto2, Taikichi Hashimoto2, Masaru Nakagawa1, Masami Ito1 and Takeshi Ogura1,+

1Department of Internal Medicine and 2Clinical Laboratory, Toneyama National Hospital, Toyonaka, Osaka, Japan

Background: The involvements of interleukin-6 (IL-6) and fibrinogen in cancer development were elucidated independently, irrespective of IL-6 activity to induce fibrinogen. This study was undertaken to clarify the clinicopathological association of these molecules in lung cancer patients with malignant pleurisy.

Methods: IL-6, fibrinogen and the related molecules in blood and pleural effusion of 38 patients were assayed at 3-day intervals.

Results: IL-6 levels were elevated in sera of 27 cases (71.1%) and in all the effusions with mean values of 20.5 and 9970.5 pg/ml, respectively. Their correlation in 22 cases who were examined on the same day was statistically strong (r = 0.902, p < 0.0001). Occasional elevations of tumor necrosis factor-{alpha} were independent of IL-6 elevation. Levels of plasma fibrinogen, fibrin(ogen) degradation products (FDP) and C-reactive protein (CRP) were more frequently elevated in the IL-6-elevated cases than those without IL-6 elevation. In all pleural effusions, fibrinogen levels were significantly decreased to <150 mg/dl with large elevations of FDP level. Immunocytologic­ally, IL-6 was detected in cancer cells in 16 cases of adenocarcinoma in addition to host pleural cells, but its cellular positivity was not reflected in the IL-6 level in each pleural effusion.

Conclusion: Compared with lung cancer patients without malignant pleurisy, IL-6, fibrinogen, FDP and CRP levels in patients with malignant pleurisy were increased more frequently in their peripheral blood. These were basically attributed to systemic leakage of IL-6 from the affected pleural cavity, in which plasma fibrinogen induced in response to serum IL-6 was exudated and degraded predominantly to FDP.

+ For reprints and all correspondence; Takeshi Ogura, Department of Internal Medicine, Toneyama National Hospital, 5–1–1 Toneyama, Toyonaka, Osaka 560-8552, JapanAbbreviations: IL-6, interleukin-6; CRP, C-reactive protein; FDP, fibrin(ogen) degradation product; TNF-{alpha}, tumor necrosis factor-{alpha}


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ChestHome page
N. Hata, K. Tanaka, T. Imaizumi, T. Ohara, T. Ohba, T. Shinada, and T. Takano
Clinical Significance of Pleural Effusion in Acute Aortic Dissection
Chest, March 1, 2002; 121(3): 825 - 830.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.